Biomarin Pharmaceutical (BMRN) Leads The Pack In Pre-Market Activity

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Biomarin Pharmaceutical ( BMRN) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Biomarin Pharmaceutical as such a stock due to the following factors:

  • BMRN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $161.5 million.
  • BMRN traded 17,965 shares today in the pre-market hours as of 8:53 AM.
  • BMRN is up 5.4% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in BMRN with the Ticky from Trade-Ideas. See the FREE profile for BMRN NOW at Trade-Ideas

More details on BMRN:

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently there are 12 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Biomarin Pharmaceutical has been 1.6 million shares per day over the past 30 days. Biomarin has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 28.2% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half